Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

Donor lymphocyte infusion (DLI), a standard relapse treatment after allogeneic stem cell transplantation (AlloSCT), has limited efficacy and often triggers GVHD. We hypothesized that after AlloSCT tumor-infiltrating donor lymphocytes could be costimulated ex vivo to preferentially activate/expand antitumor effectors. We tested the feasibility and safety of costimulated, tumor-derived donor lymphocyte (TDL) infusion in a phase 1 trial. Tumor was resected from 8 patients with B-cell malignancy progression post-AlloSCT; tumor cell suspensions were costimulated with anti-CD3/anti-CD28 Ab-coated magnetic beads and cultured to generate TDL products for each patient. Costimulation yielded increased proportions of T-bet(+)FoxP3(-) type 1 effector donor T cells. A median of 2.04 × 10(7) TDL/kg was infused; TDLs were well tolerated, notably without GVHD. Two transient positron emission tomography (PET) responses and 2 mixed responses were observed in these refractory tumors. TDL are a feasible, tolerable, and novel donor cell therapy alternative for relapse after AlloSCT.

[1]  R. Gascoyne,et al.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Fozza,et al.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications , 2010, Advances in hematology.

[3]  F. Johnson,et al.  Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation , 2009, Clinical Cancer Research.

[4]  D. Porter,et al.  Graft-versus-host disease after donor leukocyte infusions: presentation and management. , 2008, Best practice & research. Clinical haematology.

[5]  S. Steinberg,et al.  Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[7]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[8]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[9]  J. Byrne,et al.  Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[10]  S. Rosenberg,et al.  Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.

[11]  W. Matsui,et al.  Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. , 2005, Cancer research.

[12]  A. Flake,et al.  Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. , 2002, Blood.

[13]  W. Wilson,et al.  Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. , 2002, Cytotherapy.

[14]  M. V. van Oers,et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.